A novel series of antagonists of the human A(2A) receptor have been identified and have been shown to display good potency and high degrees of selectivity over other receptor sub-types. Displaying in vivo potency in commonly used disease models and high oral bio-availability, this class of compounds may serve as clinically useful treatments for the relief of the symptoms associated with Parkinson's disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2009.03.142 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!